SOPHiA GENETICS

SOPHiA GENETICS EBIT Margin

The EBIT Margin (Operating Margin) of SOPHiA GENETICS (SOPH) as of Oct 21, 2026 is -98.10 %. In the previous year, EBIT Margin (Operating Margin) was -102.14 % — a change of -3.95% (higher).

EBIT Margin

-98.10 %

YoY

-3.95%

Last updated:

EBIT Margin (Operating Margin) of SOPHiA GENETICS is 2025 -98.10 % . EBIT Margin (Operating Margin) of SOPHiA GENETICS was 2024 -102.14 % . It decreases by -3.95% higher compared to the previous year.

For SOPHiA GENETICS, the operating (EBIT) margin of -104.2% is up versus -183.1% a few years ago.

The SOPHiA GENETICS EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2019
-129.09 USD
Jan 1, 2020
-142.20 USD
Jan 1, 2021
-180.15 USD
Jan 1, 2022
-184.66 USD
Jan 1, 2023
-119.97 USD
Jan 1, 2024
-102.14 USD
Jan 1, 2025
-98.10 USD
The SOPHiA GENETICS EBIT Margin history
YEAREBIT MarginYoY
-98.10 %-3.95%
-102.14 %-14.86%
-119.97 %-35.03%
-184.66 %+2.50%
-180.15 %+26.68%
-142.20 %+10.16%
-129.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SOPHiA GENETICS Stock analysis

What does SOPHiA GENETICS do? Sophia Genetics SA is a Swiss company that was founded in 2011. The idea behind it was to improve genome sequencing and data analysis in order to make faster and more precise medical diagnoses. Sophia Genetics has since become a leading provider of artificial intelligence and data analysis in the medical field. The business model of Sophia Genetics is based on providing doctors and medical facilities with corresponding data analysis tools and platforms. Sophia Genetics' algorithms help to identify genetic anomalies and develop personalized therapies. This personalized medicine aims to improve healthcare. Sophia Genetics is divided into various sectors. The core sectors include oncology, pediatrics, cardiology, and neurology. In these specialized fields, Sophia Genetics' platforms and tools are used to optimize genome sequencing and data analysis, thus enabling faster and more precise diagnoses. The company offers a variety of products that help doctors and medical facilities create successful diagnoses and therapies. Sophia Genetics' flagship product is the Sophia Artificial Intelligence (AI) platform. This platform is used by doctors, clinics, and research institutions to analyze complex data and identify the genetic causes of diseases. The Sophia AI platform provides fast, precise, and secure genome sequencing and data analysis. Sophia Genetics also offers the Sophia DDM system. The DDM system is a cloud-based data exchange system that provides doctors and medical facilities with a secure way to exchange confidential medical data. The system also allows for the collection and analysis of information about diseases and disease progression in the population, in order to enable better healthcare. Another important product of Sophia Genetics is the Sophia Hereditary Cancer Solution. This product helps in the early detection of hereditary cancer. The Sophia Hereditary Cancer Solution provides fast and precise genetic diagnostics to identify family members at increased risk of cancer and take appropriate measures. Another product of Sophia Genetics is Sophia Radiomics. This software uses artificial intelligence and machine learning to detect and characterize diseases based on X-ray and CT scans. By analyzing large amounts of data, the Sophia Radiomics software can assist doctors in making more precise diagnoses and better treatment decisions. Sophia Genetics relies on close collaboration with medical facilities and research institutions worldwide. The company now has customers in over 60 countries and is a partner to more than 1,000 hospitals worldwide. Sophia Genetics' platforms and tools have already helped many people to be diagnosed and treated faster and more accurately. Overall, Sophia Genetics is an innovative company that has revolutionized medical diagnostics. With its advanced platforms and tools, the company provides doctors and medical facilities with an excellent opportunity to develop personalized therapies and enable better healthcare. SOPHiA GENETICS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SOPHiA GENETICS stock

EBIT Margin (Operating Margin) of SOPHiA GENETICS is -98.10 % in 2025.

EBIT Margin (Operating Margin) of SOPHiA GENETICS changed from -102.14 % to -98.10 %, representing a -3.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) SOPHiA GENETICS since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s SOPHiA GENETICS with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — SOPHiA GENETICS

All Key Metrics — SOPHiA GENETICS